Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Udaya, Valluri"'
Autor:
Genevieve Neal-Perry, Antonio Cano, Samuel Lederman, Rossella E. Nappi, Nanette Santoro, Wendy Wolfman, Marci English, Catherine Franklin, Udaya Valluri, Faith D. Ottery
Publikováno v:
Obstetrics & Gynecology. 141:737-747
Autor:
Ciro Esposito, Botond Csiky, Michael Schömig, Udaya Valluri, Jonathan Barratt, Władysław Sułowicz, Michael Reusch
Publikováno v:
Advances in Therapy
Introduction Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This European, phase 3, randomized, open-label, active-controlled stu
Autor:
Ciro Esposito, Avtandil Tataradze, Udaya Valluri, Władysław Sułowicz, Michael Reusch, Evgeny Shutov, Nada Dimkovic, Branislav Andric
Publikováno v:
Nephrology Dialysis Transplantation
Background Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of chronic kidney disease (CKD) anemia. Methods This Phase 3, multicenter, randomized, double-blind, placebo-controlled study examined p
Autor:
Vishala Chindalore, Ying Cao, Tong Zhu, Wenhui Zhang, Bola Akinlade, Taiji Sawamoto, Udaya Valluri, Selina Moy
Publikováno v:
Clinical Drug Investigation
Background Methotrexate is frequently used to treat rheumatoid arthritis. Peficitinib (ASP015K; Smyraf®), an oral Janus kinase inhibitor indicated for the treatment of rheumatoid arthritis, may be coadministered with methotrexate. Objective The obje
Autor:
Michael Reusch, Branislav Andrić, Jonathan Barratt, Udaya Valluri, Michael Schömig, Christophe Mariat, Avtandil Tataradze
Publikováno v:
Nephrology Dialysis Transplantation
Background Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD). Methods This randomized, open-label, active-controlled Phase 3 study com
Autor:
Jonathan Barratt, Branislav Andric, Avtandil Tataradze, Michael Schömig, Michael Reusch, Udaya Valluri, Christophe Mariat
Publikováno v:
Nephrology Dialysis Transplantation. 37:805-805
Autor:
Christophe Mariat, Udaya Valluri, Avtandil Tataradze, Jonathan Barratt, Michael Schömig, Branislav Andrić, Michael Reusch
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anaemia in patients (pts) with chronic kidney disease (CKD). Efficacy and safety of roxadustat compared with darbepoet
Autor:
Xuegong Wang, Kim Papp, Udaya Valluri, Ryo Tainaka, Christian Schwabe, Mysore S. Anil Kumar, Tong Zhu
Publikováno v:
Biopharmaceutics & Drug Disposition. 39:245-255
This study evaluated the pharmacokinetics (PK), efficacy, safety, and tolerability of bleselumab - a fully-human anti-CD40 monoclonal recombinant IgG4. Patients with moderate-to-severe psoriasis were randomized on day 1 to receive bleselumab or place
Autor:
Tong Zhu, Kathy Cho, Mark Matson, Taiji Sawamoto, Michaelene Lewand, Udaya Valluri, James Keirns, Kenneth C. Lasseter, Suzanne K. Swan, John Holman, Ying Jun Cao
Publikováno v:
Clinical Pharmacology in Drug Development. 5:435-449
Two randomized, double-blind, placebo-controlled studies are reported that had the objective to evaluate the pharmacokinetics, pharmacodynamics, and safety of ASP015K (peficitinib), a Janus kinase (JAK) inhibitor, in healthy subjects. The single-dose
Autor:
Mysore S, Anil Kumar, Kim, Papp, Ryo, Tainaka, Udaya, Valluri, Xuegong, Wang, Tong, Zhu, Christian, Schwabe
Publikováno v:
Biopharmaceutics & Drug Disposition
This study evaluated the pharmacokinetics (PK), efficacy, safety, and tolerability of bleselumab – a fully‐human anti‐CD40 monoclonal recombinant IgG4. Patients with moderate‐to‐severe psoriasis were randomized on day 1 to receive bleseluma